Efficacy and safety of denosumab treatment for Korean patients with Stage 3b-4 chronic kidney disease and osteoporosis.

BACKGROUND/AIMS: We evaluated the efficacy and safety of denosumab treatment in severe chronic kidney disease (CKD) patients with osteoporosis. We also investigated whether the treatment affects the coronary artery calcifications. METHODS: Twenty-seven postmenopausal women with Stage 3b-4 CKD and osteoporosis were enrolled. Twenty patients received denosumab plus calcium carbonate and vitamin D, and seven controls received calcium carbonate and vitamin D for 1 year. Dual-energy X-ray absorptiometry and coronary artery calcium (CAC) scoring computed tomography were performed before and after treatment. Hypocalcemic symptoms and serum calcium levels were evaluated. RESULTS: After 1 year of treatment, the percent changes of femur neck (3.6 ± 3.2% vs. -0.7 ± 4.4%, p = 0.033) and total hip (3.4 ± 3.8% vs. -1.9 ± 2.1%, p = 0.001) bone mineral density (BMD) were significantly increased in the denosumab treated group compared to the control group. However, the percent change of lumbar spine BMD did not differ between two groups (5.6 ± 5.9% vs. 2.7 ± 3.9%, p = 0.273). The percent change of bone alkaline phosphatase was significantly different in the denosumab-treated group and control group (-31.1 ± 30.0% vs. 0.5 ± 32.0%, p = 0.027). CAC scores did not differ between groups. No hypocalcemic events occurred in both groups. CONCLUSION: If carefully monitored and supplemented with calcium and vitamin D, denosumab treatment for 1 year provides significant benefits in patients with Stage 3b-4 CKD and osteoporosis. However, denosumab treatment did not affect coronary artery calcifications in these patients.

Anti-inflammatory and analgesic effects of the aqueous extract of corni fructus in murine RAW 264.7 macrophage cells.

Corni fructus is the fruit of Cornus officinalis Sieb. et Zucc, which is classified into the dogwood family of Cornaceae. Corni fructus has antineoplastic, antioxidative, and antidiabetic effects, but its anti-inflammatory and analgesic effects are unknown. Here, we investigated the anti-inflammatory and analgesic effects of an aqueous extract of corni fructus using murine RAW 264.7 macrophage cells. For this study, we used the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, western blot analysis, prostaglandin (PG) E(2) immunoassay, and nitric oxide (NO) detection. In addition, the analgesic effect of corni fructus was assessed by the acetic acid-induced writhing response in mice. The aqueous extract of corni fructus suppressed PGE(2) synthesis and NO production by inhibiting the lipopolysaccharide-induced expression of cyclooxygenase (COX)-2 and inducible NO synthase (iNOS) in murine RAW 264.7 macrophage cells. The extract also suppressed increases in nuclear factor-kappaB (NF-kappaB) levels in the nucleus. In vivo study showed that the extract suppressed the acetic acid-induced writhing response in mice. The aqueous extract of corni fructus exerts anti-inflammatory and analgesic effects by suppressing COX-2 and iNOS expression through the down-regulation of NF-kappaB binding activity.

Aqueous extract of Anemarrhena rhizome increases cell proliferation and neuropeptide Y expression in the hippocampal dentate gyrus on streptozotocin-induced diabetic rats.

In this study, the effects of the aqueous extract of Anemarrhena rhizome on cell proliferation and neuropeptide Y expression in the dentate gyrus of streptozotocin-induced diabetic rats were investigated via immunohistochemistry for 5-bromo-2'-deoxyuridine (BrdU) and neuropeptide Y. The results showed that the treatment with 50 to 200 microg/kg/day for 7 days of the aqueous extract of Anemarrhena rhizome increased new cell formation and neuropeptide Y expression in the dentate gyrus of diabetic rats reduced by the treatment with streptozotocin in rat.